Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148

Jasas, Kevin; Fyles, Anthony; Elit, L.; Hoskins, Paul; Biagi, Jim; Dubuc-Lissoir, Josée; Matthews, Sarah; Dancey, Janet; Eisenhauer, Elizabeth; Oza, Amit M.

doi:10.1200/jco.2004.22.90140.5019

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR inhibitors used as anticancer therapy have been associated with the distressing and common symptom of pruritus. The incidence rates of all‐grade and high‐grade pruritus for patients treated with the EGFR inhibitors cetuximab , erlotinib , and panitumumab were 31% and 2% (Table ). The highest incidence rate of pruritus is seen in patients treated with panitumumab, followed by cetuximab and erlotinib.…”

Section: Incidence Of Pruritus With These Targeted Agentsmentioning

confidence: 99%

Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4

et al. 2013

View full text Add to dashboard Cite

In the past decade, the expanded use of targeted anticancer drugs has significantly prolonged survival in patients treated for a variety of cancers. Despite their increased specificity, agents such as epidermal growth factor receptor inhibitors (EGFRIs), BRAF inhibitors, and targeted immunotherapies have commonly been associated with a number of dermatologic adverse events, often necessitating treatment modifications and negatively impacting patients' quality of life. Although toxicities such as rash and xerosis are frequently discussed, symptomatic pruritus, or itch, has emerged as an important, and frequently neglected, event. The present study reviews the incidence and clinical presentation of pruritus with the EFGRIs, and with two novel anti-melanoma drugs, vemurafenib and ipilimumab, with a focus on the putative underlying pathophysiology, and current management strategies.

show abstract

Section: Incidence Of Pruritus With These Targeted Agentsmentioning

confidence: 99%

Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These disappointing results could be related to the high toxicity and led to significant dose reductions and delays. In clinical trials, erlotinib has shown anticancer activity in several malignancies, including lung, pancreas, ovarian, head and neck, endometrial and biliary tract cancers [97–101]. It has been found to be safe and well tolerated with the most common side effects being diarrhea, rash, nausea, headache, emesis and fatigue.…”

Section: Egfr Inhibition and Activation Of Apoptosismentioning

confidence: 99%

EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?

Kanwar¹,

Nautiyal²

2010

CDT

View full text Add to dashboard Cite

In the past 10 to 15 years, a considerable progress has been made in the treatment of gastrointestinal (GI) related malignancies, as a number of agents expanded from only one in 1995 to seven in 2006. Current review describes the recent role of targeted therapies, specifically EGFR inhibitors in the treatment of GI cancers. Importance of dietary agents in the treatment and prevention of GI cancers is also reviewed.

show abstract

“…Numerous other targeted agents have been investigated with variable disappointing results in recurrent and metastatic endometrial cancer. These included aflibercept (VEGF Trap‐Eye) with a high‐affinity binding to VEGF‐A, VEGF‐B, and placental growth factor [28,29]; thalidomide with antiangiogenesis effect [30]; gefitinib and erlotinib, two tyrosine kinase inhibitors [31,32]; cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR) [33]; trastuzumab and lapatinib, both EGFR type 2 (HER2)‐related inhibitors that affect signal transduction [34–36]; and temsirolimus and ridaforolimus, which block the phosphoinositide 3‐kinase/AKT/mTOR pathway [37,38]. Other kinase inhibitors studied are sunitinib, brivanib, sorafenib, and imatinib [39].…”

Section: Other Gynecologic Cancersmentioning

confidence: 99%